863 related articles for article (PubMed ID: 29471939)
1. Tet2-Mediated Clonal Hematopoiesis Accelerates Heart Failure Through a Mechanism Involving the IL-1β/NLRP3 Inflammasome.
Sano S; Oshima K; Wang Y; MacLauchlan S; Katanasaka Y; Sano M; Zuriaga MA; Yoshiyama M; Goukassian D; Cooper MA; Fuster JJ; Walsh K
J Am Coll Cardiol; 2018 Feb; 71(8):875-886. PubMed ID: 29471939
[TBL] [Abstract][Full Text] [Related]
2. Clonal Hematopoiesis of Indeterminate Potential With Loss of
Lin AE; Bapat AC; Xiao L; Niroula A; Ye J; Wong WJ; Agrawal M; Farady CJ; Boettcher A; Hergott CB; McConkey M; Flores-Bringas P; Shkolnik V; Bick AG; Milan D; Natarajan P; Libby P; Ellinor PT; Ebert BL
Circulation; 2024 Apr; 149(18):1419-1434. PubMed ID: 38357791
[TBL] [Abstract][Full Text] [Related]
3. The selective NLRP3-inflammasome inhibitor MCC950 reduces myocardial fibrosis and improves cardiac remodeling in a mouse model of myocardial infarction.
Gao R; Shi H; Chang S; Gao Y; Li X; Lv C; Yang H; Xiang H; Yang J; Xu L; Tang Y
Int Immunopharmacol; 2019 Sep; 74():105575. PubMed ID: 31299609
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1β and islet cellular death.
Matsuoka T; Yoshimatsu G; Sakata N; Kawakami R; Tanaka T; Yamada T; Yoshida Y; Hasegawa S; Kodama S
Sci Rep; 2020 Oct; 10(1):17920. PubMed ID: 33087823
[TBL] [Abstract][Full Text] [Related]
5. The covalent NLRP3-inflammasome inhibitor Oridonin relieves myocardial infarction induced myocardial fibrosis and cardiac remodeling in mice.
Gao RF; Li X; Xiang HY; Yang H; Lv CY; Sun XL; Chen HZ; Gao Y; Yang JS; Luo W; Yang YQ; Tang YH
Int Immunopharmacol; 2021 Jan; 90():107133. PubMed ID: 33168408
[TBL] [Abstract][Full Text] [Related]
6. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice.
Fuster JJ; MacLauchlan S; Zuriaga MA; Polackal MN; Ostriker AC; Chakraborty R; Wu CL; Sano S; Muralidharan S; Rius C; Vuong J; Jacob S; Muralidhar V; Robertson AA; Cooper MA; Andrés V; Hirschi KK; Martin KA; Walsh K
Science; 2017 Feb; 355(6327):842-847. PubMed ID: 28104796
[TBL] [Abstract][Full Text] [Related]
7. BRCC3-Mediated NLRP3 Deubiquitylation Promotes Inflammasome Activation and Atherosclerosis in
Yalcinkaya M; Liu W; Thomas LA; Olszewska M; Xiao T; Abramowicz S; Papapetrou EP; Westerterp M; Wang N; Tabas I; Tall AR
Circulation; 2023 Nov; 148(22):1764-1777. PubMed ID: 37781816
[TBL] [Abstract][Full Text] [Related]
8. NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice-Brief Report.
van der Heijden T; Kritikou E; Venema W; van Duijn J; van Santbrink PJ; Slütter B; Foks AC; Bot I; Kuiper J
Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1457-1461. PubMed ID: 28596375
[TBL] [Abstract][Full Text] [Related]
9. NLRP3 regulates alveolar bone loss in ligature-induced periodontitis by promoting osteoclastic differentiation.
Chen Y; Yang Q; Lv C; Chen Y; Zhao W; Li W; Chen H; Wang H; Sun W; Yuan H
Cell Prolif; 2021 Feb; 54(2):e12973. PubMed ID: 33382502
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Pharmacology of the NLRP3 Inflammasome Inhibitor CP-456,773 (CRID3) in Murine Models of Dermal and Pulmonary Inflammation.
Primiano MJ; Lefker BA; Bowman MR; Bree AG; Hubeau C; Bonin PD; Mangan M; Dower K; Monks BG; Cushing L; Wang S; Guzova J; Jiao A; Lin LL; Latz E; Hepworth D; Hall JP
J Immunol; 2016 Sep; 197(6):2421-33. PubMed ID: 27521339
[TBL] [Abstract][Full Text] [Related]
11. An NLRP3-specific inflammasome inhibitor attenuates crystal-induced kidney fibrosis in mice.
Ludwig-Portugall I; Bartok E; Dhana E; Evers BD; Primiano MJ; Hall JP; Franklin BS; Knolle PA; Hornung V; Hartmann G; Boor P; Latz E; Kurts C
Kidney Int; 2016 Sep; 90(3):525-39. PubMed ID: 27262364
[TBL] [Abstract][Full Text] [Related]
12. The selective NLRP3 inflammasome inhibitor MCC950 alleviates cholestatic liver injury and fibrosis in mice.
Qu J; Yuan Z; Wang G; Wang X; Li K
Int Immunopharmacol; 2019 May; 70():147-155. PubMed ID: 30802677
[TBL] [Abstract][Full Text] [Related]
13. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
[TBL] [Abstract][Full Text] [Related]
14. Selective NLRP3 inflammasome inhibitor reduces neuroinflammation and improves long-term neurological outcomes in a murine model of traumatic brain injury.
Xu X; Yin D; Ren H; Gao W; Li F; Sun D; Wu Y; Zhou S; Lyu L; Yang M; Xiong J; Han L; Jiang R; Zhang J
Neurobiol Dis; 2018 Sep; 117():15-27. PubMed ID: 29859317
[TBL] [Abstract][Full Text] [Related]
15. Microglial NLRP3 inflammasome activation mediates IL-1β release and contributes to central sensitization in a recurrent nitroglycerin-induced migraine model.
He W; Long T; Pan Q; Zhang S; Zhang Y; Zhang D; Qin G; Chen L; Zhou J
J Neuroinflammation; 2019 Apr; 16(1):78. PubMed ID: 30971286
[TBL] [Abstract][Full Text] [Related]
16. The NLRP3 inflammasome modulates glycolysis by increasing PFKFB3 in an IL-1β-dependent manner in macrophages.
Finucane OM; Sugrue J; Rubio-Araiz A; Guillot-Sestier MV; Lynch MA
Sci Rep; 2019 Mar; 9(1):4034. PubMed ID: 30858427
[TBL] [Abstract][Full Text] [Related]
17. Evidence against a role for NLRP3-driven islet inflammation in db/db mice.
Kammoun HL; Allen TL; Henstridge DC; Barre S; Coll RC; Lancaster GI; Cron L; Reibe S; Chan JY; Bensellam M; Laybutt DR; Butler MS; Robertson AAB; O'Neill LA; Cooper MA; Febbraio MA
Mol Metab; 2018 Apr; 10():66-73. PubMed ID: 29478918
[TBL] [Abstract][Full Text] [Related]
18. CRISPR-Mediated Gene Editing to Assess the Roles of Tet2 and Dnmt3a in Clonal Hematopoiesis and Cardiovascular Disease.
Sano S; Oshima K; Wang Y; Katanasaka Y; Sano M; Walsh K
Circ Res; 2018 Jul; 123(3):335-341. PubMed ID: 29728415
[TBL] [Abstract][Full Text] [Related]
19. MCC950 blocks enhanced interleukin-1β production in patients with NLRP3 low penetrance variants.
Schuh E; Groß CJ; Wagner D; Schlüter M; Groß O; Kümpfel T
Clin Immunol; 2019 Jun; 203():45-52. PubMed ID: 30974290
[TBL] [Abstract][Full Text] [Related]
20. The Nlrp3 Inflammasome Orchestrates Mobilization of Bone Marrow-Residing Stem Cells into Peripheral Blood.
Lenkiewicz AM; Adamiak M; Thapa A; Bujko K; Pedziwiatr D; Abdel-Latif AK; Kucia M; Ratajczak J; Ratajczak MZ
Stem Cell Rev Rep; 2019 Jun; 15(3):391-403. PubMed ID: 31089880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
